Trump Administration To Award $472M More To Moderna For Coronavirus Vaccine Candidate Development; Media Outlets Report On Other COVID-19 Vaccine News

POLITICO: Trump administration invests $472M more in Moderna vaccine candidate
“The Trump administration is going to pump another $472 million into expanding Moderna’s clinical trial to test the safety and efficacy of its coronavirus vaccine candidate…” (Roubein, 7/26).

Reuters: Moderna gets further $472 million U.S. award for coronavirus vaccine development
“…The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna’s vaccine candidate. … BARDA’s total funding for the experimental vaccine of Moderna, the first in the United States to begin human trials of a coronavirus vaccine, is now about $955 million…” (Ponnezhath, 7/26).

The Atlantic: A Vaccine Reality Check (Zhang, 7/24).

CNN: The world’s hopes for a coronavirus vaccine may run in these health care workers’ veins (Walsh et al., 7/27).

New Yorker: The Long Game of Coronavirus Research (Groopman, 7/23).

VICE: It’s OK If Countries Hack Each Other’s Vaccines (Bender, 7/27).

Wall Street Journal: A Big Unknown in Covid-19 Vaccine Development: How Long Will Protection Last? (Hopkins et al., 7/26).

Washington Post: A trial for coronavirus vaccine researchers: Making sure black and Hispanic communities are included in studies (Johnson, 7/26).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.